BMO Capital Markets reaffirmed their hold rating on shares of Gilead Sciences, Inc. (NASDAQ:GILD) in a research note published on Friday morning. BMO Capital Markets currently has a $82.00 target price on the biopharmaceutical company’s stock.

A number of other research analysts also recently weighed in on the stock. Maxim Group reissued a hold rating on shares of Gilead Sciences in a research report on Thursday. Leerink Swann increased their target price on shares of Gilead Sciences from $84.00 to $85.00 and gave the company a market perform rating in a research report on Thursday. William Blair reissued a buy rating on shares of Gilead Sciences in a research report on Thursday. Berenberg Bank set a $96.00 target price on shares of Gilead Sciences and gave the company a buy rating in a research report on Thursday. Finally, Zacks Investment Research downgraded shares of Gilead Sciences from a hold rating to a sell rating in a research report on Wednesday. One analyst has rated the stock with a sell rating, twelve have issued a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Gilead Sciences currently has a consensus rating of Buy and a consensus price target of $85.64.

Shares of Gilead Sciences (NASDAQ GILD) traded down 0.47% during midday trading on Friday, reaching $81.21. 9,188,325 shares of the company’s stock traded hands. The stock has a 50-day moving average price of $82.63 and a 200 day moving average price of $72.65. The firm has a market cap of $106.05 billion, a PE ratio of 8.82 and a beta of 1.14. Gilead Sciences has a 12 month low of $63.76 and a 12 month high of $86.27.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.11 by $0.45. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The firm had revenue of $7.14 billion during the quarter, compared to the consensus estimate of $6.35 billion. During the same period in the prior year, the firm earned $3.08 EPS. The company’s revenue was down 8.2% compared to the same quarter last year. Equities research analysts predict that Gilead Sciences will post $8.74 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This story was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another site, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/10/21/gilead-sciences-inc-gild-given-hold-rating-at-bmo-capital-markets.html.

The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 28th. Stockholders of record on Friday, September 15th were given a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a dividend yield of 2.56%. The ex-dividend date was Thursday, September 14th. Gilead Sciences’s dividend payout ratio (DPR) is currently 22.58%.

In other news, insider John C. Martin sold 73,333 shares of the firm’s stock in a transaction on Tuesday, August 1st. The shares were sold at an average price of $75.86, for a total transaction of $5,563,041.38. Following the sale, the insider now owns 3,199,969 shares in the company, valued at approximately $242,749,648.34. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Gregg H. Alton sold 15,000 shares of the firm’s stock in a transaction on Tuesday, August 1st. The shares were sold at an average price of $75.88, for a total transaction of $1,138,200.00. Following the sale, the executive vice president now owns 106,113 shares in the company, valued at approximately $8,051,854.44. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 446,819 shares of company stock worth $36,338,919. Corporate insiders own 1.30% of the company’s stock.

Institutional investors have recently bought and sold shares of the company. Keel Point LLC grew its holdings in shares of Gilead Sciences by 0.4% during the 1st quarter. Keel Point LLC now owns 3,111 shares of the biopharmaceutical company’s stock valued at $211,000 after purchasing an additional 11 shares during the last quarter. Paradigm Financial Advisors LLC grew its holdings in shares of Gilead Sciences by 0.3% during the 2nd quarter. Paradigm Financial Advisors LLC now owns 8,723 shares of the biopharmaceutical company’s stock valued at $617,000 after purchasing an additional 26 shares during the last quarter. West Oak Capital LLC grew its holdings in shares of Gilead Sciences by 0.7% during the 2nd quarter. West Oak Capital LLC now owns 4,666 shares of the biopharmaceutical company’s stock valued at $330,000 after purchasing an additional 32 shares during the last quarter. First Heartland Consultants Inc. grew its holdings in shares of Gilead Sciences by 0.4% during the 2nd quarter. First Heartland Consultants Inc. now owns 8,927 shares of the biopharmaceutical company’s stock valued at $632,000 after purchasing an additional 39 shares during the last quarter. Finally, Princeton Portfolio Strategies Group LLC grew its holdings in shares of Gilead Sciences by 0.4% during the 2nd quarter. Princeton Portfolio Strategies Group LLC now owns 9,766 shares of the biopharmaceutical company’s stock valued at $691,000 after purchasing an additional 41 shares during the last quarter. Hedge funds and other institutional investors own 73.97% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.